Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Total Marrow and Lymphoid Irradiation (TMLI) -Based Conditioning Regimen in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant with Measurable Residual Disease

Blood (2023) 142 (Supplement 1): 2162.

https://doi.org/10.1182/blood-2023-185034

Published: 2023

Journal Articles

Outcomes of Patients Undergoing Fludarabine and Melphalan-Based Conditioning with Post-Transplant Cyclophosphamide for Peripheral Blood Stem Cell Allogeneic Hematopoietic Cell Transplant: Donor Type Effect

Blood (2023) 142 (Supplement 1): 2151.

https://doi.org/10.1182/blood-2023-187687

Published: 2023

Journal Articles

Favorable Survival Outcomes in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Fludarabine/Melphalan-Conditioning with Tacrolimus/Sirolimus-Based Gvhd Prophylaxis

Blood (2023) 142 (Supplement 1): 4959.

https://doi.org/10.1182/blood-2023-187156

Published: 2023

Journal Articles

Fractionated Total Body Irradiation and Fludarabine Based Conditioning Regimen with Post-Transplant Cyclophosphamide (PTCy) for Mismatched Related and Unrelated Donors HCT for Acute Leukemia and MDS

Blood (2023) 142 (Supplement 1): 3537.

https://doi.org/10.1182/blood-2023-187728

Published: 2023

Journal Articles

A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation (HaploHCT) with Post-Transplant Cyclophosphamide in Patients with Advanced Myelofibrosis

Haris Ali, Dongyun Yang, Sally Mokhtari, Ahmed Aribi, Joshua Mansour, Firoozeh Sahebi, Geoffrey P. Shouse, Idoroenyi Amanam, Salman Otoukesh, Anthony Stein, Stephen J. Forman, Guido Marcucci, Ryotaro Nakamura, Monzr M. Al Malki

Blood (2023) 142 (Supplement 1): 3566.

https://doi.org/10.1182/blood-2023-190449

Published: 2023

Journal Articles

Improving Outcomes of Peripheral Blood Stem Cell (PBSC) HLA-Mismatched Unrelated Donor (MMUD) Hematopoietic Cell Transplantation (HCT): Effect of Graft Versus Host Disease (GVHD) Prophylaxis

Blood (2023) 142 (Supplement 1): 4896.

https://doi.org/10.1182/blood-2023-187909

Published: 2023

Journal Articles

Real World Outcomes of Patients with Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation after Induction with Liposomal Daunorubicin-Cytarabine (CPX-351)

Guneet Kaleka, Dat Ngo, Dongyun Yang, Sally Mokhtari, Guido Marcucci, Ryotaro Nakamura, Vinod Pullarkat, Caspian H. Oliai, Amandeep Salhotra

Blood (2023) 142 (Supplement 1): 5938.

https://doi.org/10.1182/blood-2023-183053

Published: 2023

Journal Articles

Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Janny M. Yao, Hanna Kim, Dongyun Yang, Sally Mokhtari, Salman Otoukesh, Shukaib Arslan, Idoroenyi Amanam, Brian J Ball, Paul B. Koller, Amandeep Salhotra, Ahmed Aribi, Andrew S. Artz, Ibrahim Aldoss, Haris Ali, Anthony S. Stein, Guido Marcucci, Stephen J Forman, Ryotaro Nakamura, Monzr M. Al Malki

Blood (2022) 140 (Supplement 1): 7580–7582.

https://doi.org/10.1182/blood-2022-167713

Published: 2022

Journal Articles

Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Blood (2022) 140 (Supplement 1): 1872–1874.

https://doi.org/10.1182/blood-2022-170323

Published: 2022

Journal Articles

Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity

Blood (2022) 140 (Supplement 1): 10624–10626.

https://doi.org/10.1182/blood-2022-167757

Published: 2022

Journal Articles

Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

Blood (2022) 140 (Supplement 1): 1890–1892.

https://doi.org/10.1182/blood-2022-169964

Published: 2022

Journal Articles

Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions

Blood (2022) 140 (Supplement 1): 6020–6022.

https://doi.org/10.1182/blood-2022-158288

Published: 2022

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL

Blood (2021) 138 (Supplement 1): 3955.

https://doi.org/10.1182/blood-2021-153125

Published: 2021

Journal Articles

The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type

Sanjeet S Dadwal, Dongyun Yang, Guido Marcucci, Sally Mokhtari, Bernard Tegtmeier, Joycelynne Palmer, Eileen P. Smith, Randy Taplitz, Andrew S. Artz, Peter T. Curtin, Ricardo Spielberger, Amandeep Salhotra, Anthony S. Stein, Stephen J Forman, Monzr M. Al Malki, Ryotaro Nakamura

Blood (2021) 138 (Supplement 1): 1776.

https://doi.org/10.1182/blood-2021-153784

Published: 2021

Journal Articles

Prediction of Graft-Versus-Host Disease in Recipients of Single Mismatched Unrelated Hematopoietic Cell Transplantation Donor Using a Highly Multiplexed Proteomic Assay, MHC-Pepseq

Karamjeet S. Sandhu, Ketevan Gendzekhadze, Dongyun Yang, Ryotaro Nakamura, Sally Mokhtari, Monzr M. Al Malki, Haris Ali, Amandeep Salhotra, Stephen J Forman, Medhat Askar, John Altin

Blood (2021) 138 (Supplement 1): 1808.

https://doi.org/10.1182/blood-2021-153597

Published: 2021

Journal Articles

A Randomized Open Label Pilot Study of Clostridium Butyricum Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation

Blood (2021) 138 (Supplement 1): 334.

https://doi.org/10.1182/blood-2021-153821

Published: 2021

Journal Articles

Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Salman Otoukesh, MD, Hany Elmariah, MDMS, Dongyun Yang, PhD, Sally Mokhtari, PhD, Madiha Siraj, Haris Ali, MD, Krishnakar Mogili, Shukaib Arslan, MD, Taiga Nishihori, MD, Chatchada Karanes, MD, Joseph Pidala, MD, Ryotaro Nakamura, MD, Claudio Anasetti, MD, Stephen J. Forman, MD, Monzr M. Al Malki, MD, Nelli Bejanyan, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-143166

Published: 2020

Journal Articles

Healthcare Resource Utilization in Transplant Patients Who Are at a Higher-Risk to Develop Cytomegalovirus Infection during Their Primary Transplant-Related Hospitalization

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-143452

Published: 2020

Journal Articles

Updated Analysis: Novel Machine-Learning-Based Sepsis Prediction Model for Patients Undergoing Hematopoietic Stem Cell Transplantation (Early Sepsis Prediction/Identification for Transplant Recipients: ESPRIT)

Zahra Eftekhari, MS, Sally Mokhtari, PhD, Tushondra Thomas, MSN, MBA, PHN, RN-BC, Dongyun Yang, PhD, Liana Nikolaenko, MD, Deron Johnson, PharmD, Jana Dickter, MD, Justine Abella Ross, PharmD, Bernard Tegtmeier, PhD D(ABMM), CIC, Eileen P. Smith, MD, Monzr M. Al Malki, MD, Ricardo Spielberger, MD, Anna B Pawlowska, MD, Argelia Sandoval, MD, John Zaia, MD, Stephen J Forman, MD, Janet Munu, BSc, MBA, RN, Sanjeet Dadwal, MD, Ryotaro Nakamura, MD

Blood (2019) 134 (Supplement_1): 4477.

https://doi.org/10.1182/blood-2019-130926

Published: 2019

Journal Articles

Large-Scale Manufacturing of CMV-CD19CAR T Cells and Characterization of Their Biologic and Immunologic Properties

Xiuli Wang, PhD, Miriam Walter, Ryan Urak, Laura Lim, Vibhuti Vyas, MS, Sally Mokhtari, PhD, Don J. Diamond, PhD, Angelo Cardoso, PhD, John Zaia, MD, Stephen J. Forman, MD, Ryotaro Nakamura, MD

Blood (2019) 134 (Supplement_1): 3247.

https://doi.org/10.1182/blood-2019-131843

Published: 2019

NARROW

Total Marrow and Lymphoid Irradiation (TMLI) -Based Conditioning Regimen in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant with Measurable Residual Disease

Outcomes of Patients Undergoing Fludarabine and Melphalan-Based Conditioning with Post-Transplant Cyclophosphamide for Peripheral Blood Stem Cell Allogeneic Hematopoietic Cell Transplant: Donor Type Effect

Favorable Survival Outcomes in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Fludarabine/Melphalan-Conditioning with Tacrolimus/Sirolimus-Based Gvhd Prophylaxis

Fractionated Total Body Irradiation and Fludarabine Based Conditioning Regimen with Post-Transplant Cyclophosphamide (PTCy) for Mismatched Related and Unrelated Donors HCT for Acute Leukemia and MDS

A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation (HaploHCT) with Post-Transplant Cyclophosphamide in Patients with Advanced Myelofibrosis

Improving Outcomes of Peripheral Blood Stem Cell (PBSC) HLA-Mismatched Unrelated Donor (MMUD) Hematopoietic Cell Transplantation (HCT): Effect of Graft Versus Host Disease (GVHD) Prophylaxis

Real World Outcomes of Patients with Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation after Induction with Liposomal Daunorubicin-Cytarabine (CPX-351)

Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity

Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL

The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type

Prediction of Graft-Versus-Host Disease in Recipients of Single Mismatched Unrelated Hematopoietic Cell Transplantation Donor Using a Highly Multiplexed Proteomic Assay, MHC-Pepseq

A Randomized Open Label Pilot Study of Clostridium Butyricum Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation

Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Healthcare Resource Utilization in Transplant Patients Who Are at a Higher-Risk to Develop Cytomegalovirus Infection during Their Primary Transplant-Related Hospitalization

Updated Analysis: Novel Machine-Learning-Based Sepsis Prediction Model for Patients Undergoing Hematopoietic Stem Cell Transplantation (Early Sepsis Prediction/Identification for Transplant Recipients: ESPRIT)

Large-Scale Manufacturing of CMV-CD19CAR T Cells and Characterization of Their Biologic and Immunologic Properties

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only